Figure 3: Inhibition of H22 tumour growth by 11β-HSD1 overexpression or 11β-HSD2 knockdown.
From: Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma
H22 cell line with 11β-HSD1 overexpression or 11β-HSD2 knockdown was s.c. injected to mice (n=6 per group). (a,b) The tumour growth was analysed by analysis of variance (*P<0.05). (c,d) The long-term survival of mice was analysed by Kaplan–Meier analysis. Data shown are representative of three reproducible experiments. The error bars represent means±s.e.m.
